Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future approaches to factor VIII inhibitor therapy.

L W Hoyer1

  • 1Holland Laboratory, American Red Cross Blood Services, Rockville, Maryland.

The American Journal of Medicine
|November 4, 1991
PubMed
Summary

Treating acquired factor VIII (FVIII) inhibitors requires understanding the immune response. New therapies focus on restoring self-tolerance by modifying the immune system, offering promising avenues for patients with FVIII inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

Thrombosis research·2001
Same author

Characterization of the immune response to factor VIII using hemophilia A* mice.

Haematologica·2001
Same author

Mechanism of the immune response to human factor VIII in murine hemophilia A.

Thrombosis and haemostasis·2001
Same author

Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer.

European journal of immunology·2000
Same author

Prevention and treatment of factor VIII inhibitors in murine hemophilia A.

Blood·2000
Same author

Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.

Thrombosis and haemostasis·1999

Area of Science:

  • Immunology
  • Hematology
  • Therapeutics

Background:

  • Acquired factor VIII (FVIII) inhibitors represent a loss of self-tolerance.
  • Effective treatment necessitates restoring this self-tolerance.

Purpose of the Study:

  • To explore novel immunotherapeutic strategies for acquired FVIII inhibitors.
  • To review current and emerging treatment options for FVIII inhibition.

Main Methods:

  • Investigating methods to restore self-tolerance, such as T-cell modulation and MHC recognition inhibition.
  • Examining FVIII-bypassing agents and inhibitor removal techniques.
  • Considering modified recombinant FVIII molecules and immunosuppressive drugs.

Main Results:

  • Experimental autoimmune diseases have shown success with immunotherapeutic approaches.
  • FVIII-bypassing agents and affinity-based inhibitor removal show promise.
  • Various treatment modalities exist, including plasmapheresis, IVIG, and cytotoxic drugs.

Conclusions:

  • Restoring self-tolerance is a key goal for treating acquired FVIII inhibitors.
  • A diverse range of therapeutic options are available, reflecting the condition's heterogeneity.
  • Further research, particularly in animal models, is needed to validate immune intervention strategies.

Related Experiment Videos